Publications

5677 Results

Alliance A031902 (CASPAR): A randomized, phase 3 trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Authors
A Rao;G Heller;C Ryan;D Vanderweele;L Lewis;A Tan;C Watt;R Chen;M Kohli;P Barata;B Gartrell;R Grubb;A Dueck;Y Wen;M Morris
Journal / Conference
J Clin Oncol 41, 2023 (suppl 6; abstr TPS277); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Genitourinary

Evaluating the impact of stratification, sample size, and randomization ratio on the power of randomized Phase 2 clinical trials

Authors
A Moseley;M LeBlanc;M Othus
Journal / Conference
Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
Year
2023
Research Committee(s)
Cancer Care Delivery

Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752

Authors
V Chung;K Guthrie;M Pishvaian;K Reiss;A Lowy;D Sohal;S Colby;E Sharon;C Allegra;E O'Reilly;E Chiorean;P Philip
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4198); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S2001

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016

Authors
M Shadman;H Li;L Rimsza;J Leonard;M Kaminski;K Spier;A Gopal;S Dakhil;M LeBlanc;S Smith;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland, oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S0016

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2207

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

Authors
B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2114

S1918: Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas

Authors
E Brem;H Li;A Beaven;P Caimi;L Cerchietti;R Olin;NL Henry;H Dillon;R Little;M LeBlanc;B Kahl;J Leonard;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1918

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Authors
B Darst;J Shen;R Madduri;A Rodriguez;Y Xiao;X Sheng;E Saunders;T Dadaev;M Brook;T Hoffmann;K Muir;P Wan;L LeMarchand;L Wilkens;Y Wang;J Schleutker;R MacInnis;D Albanes;C Tangen;Z Kote-Jarai;S Watya;J Gaziano;A Justice;D Conti;C Haiman
Journal / Conference
American Journal of Human Genetics Jul 6;110(7):1200-1206
Year
2023
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
PMID
PMID37292833
PMC
PMC10246022
Study Number(s)
S0000, SWOG-9217

A Randomized Phase 2 Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613

Authors
K Raghav;K Guthrie;S Kopetz;B Tan;C Denlinger;M Fakih;M Overman;N Dasari;L Corum;L Hicks;M Patel;B Esparaz;S Kazmi;N Alluri;S Colby;S Gholami;P Gold;EG Chiorean;H Hochster;PA Philip
Journal / Conference
ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1613